What question did this study set out to answer?

To compare allogeneic hematopoietic cell transplantation outcomes between de novo chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia across different disease-remission strata.

November 4, 2024Cancer

Comparing de novo chronic myeloid leukemia in blastic phase with Philadelphia chromosome–positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation

View Full Paper

Ask AI

Bookmark

To compare allogeneic hematopoietic cell transplantation outcomes between de novo chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia across different disease-remission strata.
Analyzed registry database records of patients undergoing allogeneic hematopoietic cell transplantation between 2002 and 2021 who received pre-transplant tyrosine kinase inhibitor therapy.
Compared transplant outcomes across negative-minimal residual disease (MRD), positive-MRD, and nonremission cohorts, excluding Ph-positive ALL patients with p210 transcripts.
In the MRD-positive cohort at transplantation, de novo CML-BP was associated with superior disease-free survival (HR 0.6, p = .0032), superior overall survival (HR 0.66, p = .027), and a lower risk of relapse (HR 0.48, p = .0051) compared to Ph-positive ALL.
BCR::ABL1 mutation status demonstrated a significant interaction with disease type (p for interaction = .0027), with de novo CML-BP showing superior disease-free survival in the mutation-positive cohort but not in the mutation-negative cohort.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Registry study reveals superior survival after transplantation in de novo blastic phase CML with minimal residual disease, indicating stem cell grafts overcome poor prognosis.

Cite This Study

Okada et al. (2024) studied this question.

synapsesocial.com/papers/6a16bcd0b13aec50ea6b76b6 https://doi.org/10.1002/cncr.35627

View Full Paper

Ask AI

Bookmark

Implication

Registry study reveals superior survival after transplantation in de novo blastic phase CML with minimal residual disease, indicating stem cell grafts overcome poor prognosis.

Comparing de novo chronic myeloid leukemia in blastic phase with Philadelphia chromosome–positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation

Key Points

Discussion

Implication

Cite This Study

Comparing de novo chronic myeloid leukemia in blastic phase with Philadelphia chromosome–positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider